Drugs /

neoantigen peptide vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A peptide-based cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon vaccination with the neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.

Clinical Trials

View Clinical Trials for neoantigen peptide vaccine

Neoantigen peptide vaccine has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating neoantigen peptide vaccine, 2 are phase 1 (2 open).

Microsatellite Stable (MSS) is the most frequent biomarker inclusion criterion for neoantigen peptide vaccine clinical trials.

Colorectal carcinoma, pancreatic adenocarcinoma, and pancreatic ductal adenocarcinoma are the most common diseases being investigated in neoantigen peptide vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Neoantigen Peptide Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating neoantigen peptide vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

NCIT ID [1]:
C165508

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.